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Editorial
Hepatic Steatosis and Hepatitis C
F. W. Ismail, S. S. Hamid
Department of Medicine, The Aga Khan University, Karachi.

Hepatic steatosis is increasingly being recognized as
a condition that may progress to end-stage liver disease. The
clinical implications of fatty liver disease are derived
mostly from its common occurrence in the general
population and its potential of causing a wide spectrum of
liver damage, ranging from simple steatosis to
steatohepatitis, advanced fibrosis and cirrhosis.1
Hepatic steatosis can occur with the use of alcohol
(alcohol-related fatty liver) or in the absence of alcohol
(nonalcoholic fatty liver disease).2 Fatty liver associated
with the use of alcohol may occur with as little as 10 oz of
alcohol ingested per week. If steatohepatitis is present but a
history of alcohol use is not, the condition is termed
nonalcoholic steatohepatitis (NASH). Fatty change in the
liver results from excessive accumulation of lipids within
hepatocytes. It is recognized on liver biopsy specimens and
thus is a morphological rather than a clinical diagnosis.1,2
Nonalcoholic fatty liver disease (NAFLD) affects
10-25% of the general population in various countries. This
prevalence increases to 57-75% in obese individuals. The
prevalence of NASH is 2-3%. NASH has been detected in
1.2-8% of patients undergoing routine liver biopsy, although
studies have reported rates as high as 7-9%.2,3
Fatty liver occurs in all age groups, with a female
predominance. It is caused by the accumulation of
triglycerides and other lipids in liver cells. In some cases,
this may be accompanied by hepatic inflammation and liver
cell death, when it is known as steatohepatitis. Potential
pathophysiological mechanisms include decreased
mitochondrial fatty acid beta-oxidation, increased
endogenous fatty acid synthesis or enhanced delivery of
fatty acids to the liver and deficient incorporation or export
of triglycerides as very-low density lipoprotein from the
liver.2
Obesity, type 2 diabetes mellitus, and
hyperlipidemia are coexisting conditions most commonly
associated with (NAFLD), but choline deficiency, obesity,
protein-calorie malnutrition, starvation, rapid weight loss
and total parenteral nutrition are important metabolic
causes. Frequently overlooked causes of NAFLD are
medications. Drugs associated with fatty liver include
amiodarone, bleomycin, warfarin, estrogens, glucocorticoids,
methotrexate and tetracycline.3
The diagnosis should be considered in all patients
with unexplained elevations in serum aminotransferases.
Noninvasive studies such as ultrasound usually identify the
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presence of a fatty liver. However, imaging techniques
cannot distinguish between benign steatosis and
steatohepatitis. Benign steatosis may be focal or diffuse,
whereas steatohepatitis usually is diffuse. No laboratory
studies can help definitively establish a diagnosis of fatty
liver or NASH. The only abnormality may be an elevated
aspartate
aminotransferase
(AST)
or
alanine
aminotransferase (ALT) level. These may be elevated as
much as 10-fold. However, the AST and ALT may be
normal in some patients with fatty liver or NASH.2
Before the diagnosis of NASH can be made, viral
markers should be tested and viral infection excluded. A
liver biopsy and histopathological examination are required
to establish the diagnosis. Specific histologic features on
biopsy include (1) steatosis, which usually is
macrovesicular but may be microvesicular or mixed; (2)
inflammation that is mixed neutrophilic and mononuclear
cell and (3) Mallory bodies and glycogen nuclei. Fibrosis or
cirrhosis may be present in advanced cases.4
One of the most important and potentially reversible
causes of NAFLD is Hepatitis C infection.4 The mechanism
by which the hepatitis C virus (HCV) causes chronic,
progressive liver damage is multifactorial, but factors other
than the virus itself have been implicated. Nonalcoholic
fatty liver disease (NAFLD) and hepatitis C virus (HCV)
related liver disease are common in the general population,
but their concurrence is 2 to 3 times higher than would be
explainable by chance alone.5 In patients with chronic HCV
infection, steatosis is attributable to a variable combination
of the mechanisms considered to play a role in the
pathogenesis of NAFLD-insulin resistance, and a direct
effect of HCV on hepatic lipid metabolism that leads to
triglyceride accumulation through inhibition of export
proteins that are required for very low density lipoprotein
(VLDL) assembly and secretion. 4,5
Hepatic steatosis is a common histological finding
occurring in more than 50% of patients with chronic
hepatitis C.6 Studies from Pakistan have indicated equally
high prevalence rates, of upto 65.7%.7 In this issue of the
journal, Khokhar8 et al report another series of 109 chronic
HCV patients who underwent a liver biopsy and the large
majority (62%) were found to have some degree of
steatosis, although they could not determine if there was a
clear association with inflammation or fibrosis.
Both host and viral factors have been demonstrated
to play an important role in the development of steatosis. In

108

those patients infected with genotype 1, steatosis appears to
be due to the co-existence of NASH with HCV and
associated with an increased body mass index (BMI).4
Another possibility is of a direct effect of specific viral
sequences on the pathogenesis of lipid accumulation. This is
especially true in the case of genotype 3.9 Furthermore,
hepatic steatosis attributed to genotype 3 correlates directly
with serum and intra hepatic titters of HCV RNA. The
resolution of steatosis after successful antiviral therapy as
well as steatosis being a sign of recurrent HCV infection in
patients with genotype 3 add convincing evidence that
steatosis is viral related. The pathogenic mechanism
induced by genotype 3 is speculative, but the correlation
between steatosis, intra hepatic HCV RNA and core protein
expression suggest a direct effect. 9
It seems likely that in patients infected with
genotype 1, BMI has a role in the pathogenesis of steatosis
while in those infected with genotype 3, steatosis may be
due to a virus-specific cytopathic effect.5 Regardless of
etiology, it is clear that the presence of steatosis contributes
to fibrosis in patients with hepatitis C.10 The degree of
fibrosis has been found to correspond to HCV RNA levels.11
Even more alarming is the finding that hepatic steatosis may
be a risk factor for the development of hepatocellular
carcinoma in these patients.12
Based on these findings, it is essential that steatosis
be diagnosed early, and be treated appropriately.
Unfortunately, treatment modalities are few and not highly
effective.1 Hepatitis C should be treated appropriately.
Abstinence from alcohol is essential. In patients with
diabetes mellitus or hyperlipidemia, good metabolic control
is recommended. No medications have been proved to
directly reduce or reverse liver damage independently of
weight loss. Only small pilot studies lasting one year or less
have been reported to date. Gemfibrozil, vitamin E, and
metformin have been shown to improve liver-test results.
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Ursodiol, betaine, vitamin E, and the thiazolidinediones led
to improvement in liver-test results as well as histologic
findings. These medications deserve further evaluation in
carefully controlled clinical trials that have sufficient
statistical power. 13
It is clear that there are many facets of hepatic
steatosis that need to be explored. Particular attention
should be paid towards preventive strategies, and future
therapy should be aimed at exploiting the interactions of
HCV with host insulin and lipid metabolism.
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